Directorate Change

    Embargoed Release: 07:00 hrs Monday 29th September 2008

                               Nanoscience Inc.                                

               (`Nanoscience', `Toumaz Holdings' or the `Group')               

                       Appointment of Executive Chairman                       

Nanoscience, henceforth to be known as Toumaz Holdings, is delighted to
announce that Sir Richard Sykes has joined the Board and will assume the role
of executive chairman in November 2008. The Group believes the appointment of
this highly regarded and experienced figure into the role of executive chairman
will help to accelerate the extraction of substantial value from its main
investee company: its wholly owned subsidiary Toumaz Technology Limited
('Toumaz'). In addition, and as previously announced, the Group's new company
name, Toumaz Holdings, reflects the primary focus of the Group's activities.

Sir Richard brings over 30 years of extensive senior executive expertise to the
Group, particularly from the pharmaceutical and healthcare sectors, where he
was most notably chairman and chief executive of Glaxo plc from 1993, which two
years later became Glaxo Wellcome plc and then GlaxoSmithKline plc until 2002.
Sir Richard was most recently Rector of Imperial College, London (from 2001 to
July 2008) and he is a Fellow of Imperial College School of Medicine, a Fellow
of King's College London and a Fleming Fellow at Lincoln College Oxford. He is
also a Fellow of the Royal Society and Academy of Medical Sciences.

Sir Richard is currently chairman of the UK Stem Cell Foundation and chairs
CATALYST, London's Council for the Advancement of Science and Industry. He is a
board member of the Higher Education Funding Council for England and chair of
the WHO International Advisory Board that oversees the International Clinical
Trials Registry Platform.

Internationally, he is chairman of the Singapore Biomedical Sciences
International Advisory Council, director of Bio*One Capital, the investment arm
of the Singapore Economic Development Board, and a member of the International
Advisory Panel of Temasek, which owns and manages the Singapore Government's
direct investments. Sir Richard is also deputy chairman of Lonza Group Ltd,
chairman of the Healthcare Advisory Group of APAX, chairman of MerLion
Pharmaceuticals Pte Ltd and a non-executive director of Abraxis BioScience Inc.

In conjunction with this appointment, Richard Rose, who is currently
non-executive chairman of the Group, will remain on the Board as the senior
non-executive director. Graham Porter, non-executive director, is stepping down
with immediate effect and the Board thanks him for his valuable contribution.
The board of Toumaz remains unchanged with Professor Christofer Toumazou as
chairman and chief technology officer of the company.

Richard Rose, non-executive chairman of Toumaz Holdings, commented:

"Sir Richard is excited about the prospects for our technology and we are
absolutely delighted to have secured his services. His experience in our sector
is second to none and in his role as executive chairman, I'm sure he will lead
the Group to the commercial success its technology deserves."

Guy Spelman, chief executive officer of Toumaz Holdings, commented:

"I am delighted that Sir Richard is joining the Group as our executive
chairman. His invaluable experience in guiding multinational growth companies
will be indispensible to Toumaz Holdings as it focuses on the opportunities
that its investments - particularly Toumaz Technology have created. I am also
pleased that Richard Rose will remain on the Board as a senior non-executive
director. The Group has thrived under his direction and we look forward to his
continued contributions. Toumaz Holdings is undergoing an exciting period of
development and we are sure that with Sir Richard as chairman, the prospects
for the Group and the potential to return substantial value to our shareholders
will become even more apparent.'

Professor Chris Toumazou FRS, chairman and CTO of Toumaz, commented:

"I have known Sir Richard for over 10 years both in his capacity as Rector of
Imperial College and Chairman of Glaxo. As Toumaz moves from a technology to a
sales business Sir Richard is the ideal leader to take us forward."

                                    -Ends-                                     

Further information:

Guy Spelman Toumaz Holding Limited 07767 338 967

Charles Cunningham/

Rose Herbert FinnCap 020 7600 1658

Vikki Krause Hansard Group 020 7245 1100

www.hansardgroup.co.uk



AIM Rules Schedule 2 Disclosure - for the purposes of paragraph (g) of schedule
2 of the AIM rules, the following information is disclosed:

Full name: Sir Richard Brook Sykes

Age: 66

Sir Richard holds or has held the following directorships with the last 5
years:

Current Directorships                     Past Directorships over last 5 years 
                                                                               
Metabometrix Limited                      Rio Tinto Plc                        
                                                                               
The UK Stem Cell Foundation               Leadership for Environment and       
                                          Development International, Inc.      
                                                                               
Omnicyte Limited                          Cephalon Holdings Limited            
                                                                               
Circassia Holdings Limited                The Russell Group of Universities    
                                                                               
Eurasian Natural Resources Corporation    The Gregor Mendel Trust Limited      
plc                                                                            
                                                                               
Hale House Management (1999) Limited      Zeneus Pharma                        
                                                                               
Livercyte Limited                                                              
                                                                               
Singapore Sciences International Advisory                                      
Council                                                                        
                                                                               
Bio*One Capital                                                                
                                                                               
Lonza Group Ltd                                                                
                                                                               
MerLion Pharmaceuticals Pte Ltd                                                
                                                                               
Abraxi BioScience Ltd                                                          
                                                                               
ENRC                                                                           
                                                                               
Bioceramic Therapeutics                                                        

No further disclosures are required to be made in relation to Sir Richard Sykes
under Schedule 2 (g) (iii) - (viii) of the AIM rules.



END